From: Minimal clinically important decline in physical function over one year: EPOSA study
Baseline | Change: 12–18 months follow-up - baseline | P | |||||
---|---|---|---|---|---|---|---|
Age, n, mean (SD), median (IQR), y | 1886 | 73.8 ± 5.0 | 73 (70.77) | ||||
Female Sex, n (%) | 1886 | 977 (51.8) | |||||
High education, n (%) | 1886 | 1120 (58.8) | |||||
Country, n (%) | 1886 | ||||||
Italy | 312 (16.8) | ||||||
The Netherlands | 407 (22.0) | ||||||
Spain | 413 (22.4) | ||||||
Sweden | 392 (23.0) | ||||||
UK | 362 (15.8) | ||||||
Clinical hand OA, n (%) | 1886 | 1842 (16.7) | |||||
Clinical hip/knee OA, n (%) | 1886 | 1845 (22.6) | |||||
AUSCAN for hand OAa, n, mean ± SD, median (IQR) | |||||||
Physical function | 1842 | 9.1 ± 15.4 | 0 (0,11) | 1842 | 1.1 ± 11.3 | 0 (0,4) | <.0001 |
Painc | 1842 | 7.6 ± 15.2 | 0 (0,5) | 1842 | 1.7 ± 14.4 | 0 (0,0) | 0.1949 |
Stiffness | 1842 | 10.0 ± 18.7 | 0 (0,25) | 1842 | 1.0 ± 17.2 | 0 (0,0) | 0.1358 |
WOMAC for hip/knee OAa, n, mean ± SD, median (IQR) | |||||||
Physical function | 1845 | 8.5 ± 13.2 | 2 (0,12) | 1845 | 1.5 ± 11.3 | 0 (−1,4) | 0.0123 |
Pain | 1845 | 10.0 ± 14.3 | 5 (0,15) | 1845 | 1.4 ± 13.2 | 0 (−5,5) | 0.2579 |
Stiffness | 1845 | 12.9 ± 18.6 | 0 (0,25) | 1845 | 0.3 ± 17.9 | 0 (0,12) | 0.0390 |
Grip strengthb, n, mean ± SD, median (IQR), kg | 1862 | 27.7 ± 10.2 | 26 (20,35) | 1826 | −1.1 ± 5.8 | −1 (−3.5,1.5) | 0.0004 |
Walking-test timec, n, mean ± SD, median (IQR), sec | 1854 | 3.3 ± 1.6 | 3 (2.3,3.8) | 1830 | 0.1 ± 1.6 | 0 (−0.5,0.6) | <.0001 |
HADS anxietyd, n, mean ± SD, median (IQR) | 1886 | 4.5 ± 3.5 | 4 (2,7) | 1872 | −0.6 ± 2.6 | −1 (−2,1) | <.0001 |
HADS depressiond, n, mean ± SD, median (IQR) | 1886 | 3.5 ± 3.0 | 3 (1,5) | 1875 | −0.3 ± 2.4 | 0 (−1,1) | <.0001 |
EQ-5D-5 Le, n, mean ± SD, median (IQR) | 1876 | 0.8 ± 0.2 | 0.8 (0.7,1.0) | 1855 | 0.0 ± 0.2 | 0 (0.0,0.1) | 0.0059 |
EQ VASf, n, mean ± SD, median (IQR) | 1882 | 76.5 ± 16.2 | 80 (70,90) | 1875 | −0.5 ± 15.6 | 0 (−10,5) | 0.0114 |